about
Lymphoma Immunotherapy: Current StatusCancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancerCombination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations.Immunotherapy advances in uro-genital malignancies.HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma.Activated d16HER2 homodimers and SRC kinase mediate optimal efficacy for trastuzumab.Sialidase NEU4 is involved in glioblastoma stem cell survival.Improved clinical outcome in indolent B-cell lymphoma patients vaccinated with autologous tumor cells experiencing immunogenic death.Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat.Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells
P50
Q26782902-95D5D20A-44CE-4CBB-96A1-1A10281586B2Q29615679-60A35EEC-C94A-419F-BE64-DFC4237CAC5DQ35527105-E8D72910-58D2-4681-B86D-2D22CF1229F7Q38555667-FBE3311D-77F9-475C-BBDA-02514082B2B0Q38574574-B79330C8-61A5-41CB-AB71-FC9020BF4068Q38884218-C1B3789F-8A71-4BB5-827D-FB411291272FQ38921685-290EEDF4-0DE0-469A-A262-F46DA2D552B1Q38962338-4B8C3149-0A19-42CD-AA69-12C4033A0B48Q38964051-98216F32-6614-4F4F-91E5-918EA58AF4B7Q39649423-AD69F9B0-3211-4C6B-915B-599B9302DB87Q48089220-A02E2464-CB81-4126-8D7C-999FAFF74AFCQ51036583-AC25DB74-E8EC-48F1-B5D2-4E7E040CBACAQ51747268-11C06F58-4775-4CB0-8E7D-FF428D9192B8Q51961830-0FB75300-A635-4D8E-A526-790F0CBAB861Q81829557-F0D2A84A-C4C3-4F32-B629-724145641695
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Roberta Zappasodi
@ast
Roberta Zappasodi
@en
Roberta Zappasodi
@es
Roberta Zappasodi
@nl
type
label
Roberta Zappasodi
@ast
Roberta Zappasodi
@en
Roberta Zappasodi
@es
Roberta Zappasodi
@nl
prefLabel
Roberta Zappasodi
@ast
Roberta Zappasodi
@en
Roberta Zappasodi
@es
Roberta Zappasodi
@nl
P106
P1153
25622040800
P21
P31
P496
0000-0002-7031-6671